Literature DB >> 25830260

Techniques for periarticular infiltration with liposomal bupivacaine for the management of pain after hip and knee arthroplasty: a consensus recommendation.

Girish P Joshi1, Fred D Cushner, John W Barrington, Adolph V Lombardi, William J Long, Bryan D Springer, Bernard N Stulberg.   

Abstract

Periarticular infiltration analgesia when used as a component of multimodal analgesia regimen has been shown to provide excellent pain relief after major joint replacement surgery. Recently, a liposomal formulation of bupivacaine (Exparel) has been approved for administration into the surgical site to produce postsurgical analgesia. It is a sustained release preparation of bupivacaine that has been shown to provide pain relief for up to 72 hours with a single local administration. Because the success of infiltration technique depends on systematic, extensive, meticulous tissue injection before surgical wound closure, a group convened to address the best practice for periarticular injection techniques for hip and knee replacement surgery. This article provides recommendations for optimal solution for injection (i.e., drug combinations or ``cocktail'' and total volume) as well as detailed description (including illustrations) of the infiltration technique for primary, revision, and unicompartmental knee arthroplasty and primary and revision hip arthroplasty using various surgical approaches.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25830260

Source DB:  PubMed          Journal:  J Surg Orthop Adv        ISSN: 1548-825X


  8 in total

1.  Liposomal bupivacaine in total hip arthroplasty: Do the results justify the cost?

Authors:  Jason A Beachler; Daniel M Kopolovich; Creighton C Tubb; Siraj A Sayeed
Journal:  J Orthop       Date:  2017-01-03

2.  To block or not to block?

Authors:  Gabriella Iohom
Journal:  Rom J Anaesth Intensive Care       Date:  2017-10

3.  Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers.

Authors:  David Rice; Justin W Heil; Lukasz Biernat
Journal:  Clin Drug Investig       Date:  2017-03       Impact factor: 2.859

4.  No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA.

Authors:  John W Barrington; Roger H Emerson; Scott T Lovald; Adolph V Lombardi; Keith R Berend
Journal:  Clin Orthop Relat Res       Date:  2017-01       Impact factor: 4.176

5.  Pain Control and Functional Milestones in Total Knee Arthroplasty: Liposomal Bupivacaine versus Femoral Nerve Block.

Authors:  Stephen Yu; Alessandra Szulc; Sharon Walton; Joseph Bosco; Richard Iorio
Journal:  Clin Orthop Relat Res       Date:  2017-01       Impact factor: 4.176

6.  Real-world insights on the use of transversus abdominis plane block with liposomal bupivacaine in the multimodal management of somatic versus visceral pain in the colorectal surgery setting.

Authors:  Nicholas C Connolly
Journal:  J Pain Res       Date:  2018-06-15       Impact factor: 3.133

7.  Cost-effective peri-operative pain management: assuring a happy patient after total knee arthroplasty.

Authors:  K Kim; A Elbuluk; S Yu; R Iorio
Journal:  Bone Joint J       Date:  2018-01       Impact factor: 5.082

8.  Liposomal Bupivacaine Plus Bupivacaine Versus Ropivacaine Plus Dexamethasone Brachial Plexus Blockade for Arthroscopic Rotator Cuff Repair: An Unblinded Randomized Controlled Trial.

Authors:  Ryan Wade Simovitch; Thomas Hernandez; Jacques T YaDeau; Michael C Grant; Christopher Pociask; Jean-Pierre P Ouanes
Journal:  JB JS Open Access       Date:  2022-04-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.